Carolyn Harris, NP
Acute Care · Avon, INNPI 1871644278
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 274 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,325 and has fallen 87.9% since, to $160 in 2025. Among acute care clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- AstraZeneca$469
- Otsuka America Pharmaceutical, Inc.$370
- GSK$246
- Exact Sciences$245
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,755100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $1,044 |
| Novo Nordisk | 55 | $1,026 |
| AstraZeneca | 27 | $469 |
| Otsuka America Pharmaceutical, Inc. | 20 | $370 |
| GSK | 11 | $246 |
| Exact Sciences | 12 | $245 |
| Phathom Pharmaceuticals, Inc. | 6 | $190 |
| Ironshore Pharmaceuticals Inc. | 8 | $161 |
| Corium, LLC | 6 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $107 |
| Eisai Inc. | 5 | $103 |
| Novartis | 7 | $99 |
| Biohaven Pharmaceuticals, Inc. | 5 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $78 |
| Bayer | 3 | $62 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Pfizer | 2 | $37 |
| Lilly USA, LLC | 2 | $35 |
| Biogen | 1 | $29 |
| Astellas Pharma US Inc | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Dynavax Technologies Corporation | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$4,763 in reported general payments places this provider in the 90th percentile of 240 acute care providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $46,206 |
| Dupixent SyringeDupilumab | 12 | $44,852 |
| MounjaroTirzepatide | 22 | $26,826 |
| JardianceEmpagliflozin | 14 | $13,120 |
| TrintellixVortioxetine Hydrobromide | 13 | $8,744 |
| XareltoRivaroxaban | 11 | $8,179 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,811 |
| MyrbetriqMirabegron | 12 | $5,427 |
| Levemir FlexpenInsulin Detemir | 15 | $2,861 |
| Gabapentin | 79 | $1,494 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $1,443 |
| Pregabalin | 37 | $1,172 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 59 | $1,079 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $987 |
| Ondansetron OdtOndansetron | 36 | $690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,026 | $46,20629 claims |
| Lilly USA, LLCMounjaro | $35 | $26,82622 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $107 | $8,74413 claims |
| GSKAnoro Ellipta | $246 | $5,81112 claims |
| Astellas Pharma US IncMyrbetriq | $27 | $5,42712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 240 acute care providers in Indiana.
Other acute care in Avon
- Melissa LorenzJeffersonville$19K
- Amara Wright-TerryMunster$17K
- Wen CaiNewburgh$12K
- Erin BarthSouth Bend$10K
- Sarah LongNewburgh$8K
- Aaron HoldermanNewburgh$8K
- Lauren ArmingtonIndianapolis$7K
- Ashley HillIndianapolis$7K
- Sara RichesonNewburgh$6K
- Sarah KachmanTerre Haute$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.